-
Mashup Score: 86
Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a…
Source: www.nejm.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 86
Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a…
Source: www.nejm.orgCategories: General Medicine News, Partners & KOLsTweet-
Out in @NEJM as @thanosdimop is speaking!! 🚨 Most important #ASH24 abstract in #MMsm: AQUILA study demonstrating OS benefit with dara x3 years in high-risk SMM. Monthly dara now can prevent Dara quad & ASCT later? Will be worth it in some patients! https://t.co/2PBwfRacuH https://t.co/KxhLx2C3HM
-
-
Mashup Score: 86
Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a…
Source: www.nejm.orgCategories: General Medicine News, Partners & KOLsTweet-
Out in @NEJM as @thanosdimop is speaking!! 🚨 Most important #ASH24 abstract in #MMsm: AQUILA study demonstrating OS benefit with dara x3 years in high-risk SMM. Monthly dara now can prevent Dara quad & ASCT later? Will be worth it in some patients! https://t.co/2PBwfRacuH https://t.co/KxhLx2C3HM
-
-
Mashup Score: 2Rahul Banerjee: Safety run-in for Teclistamab and Lenalidomide maintenance after ASCT - OncoDaily - 1 day(s) ago
Rahul Banerjee: Safety run-in for Teclistamab and Lenalidomide maintenance after ASCT / Agoston Gyula Szabo, Andrew Spencer, Antonietta Pia Falcone, Caline
Source: oncodaily.comCategories: General Medicine News, Partners & KOLsTweet-
RT @OncoDailyIO: Safety run-in for Teclistamab and Lenalidomide maintenance after ASCT - @RahulBanerjeeMD https://t.co/B8B1lPnmn3 #Cancer…
-
-
Mashup Score: 86
Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a…
Source: www.nejm.orgCategories: General Medicine News, Partners & KOLsTweet-
Out in @NEJM as @thanosdimop is speaking!! 🚨 Most important #ASH24 abstract in #MMsm: AQUILA study demonstrating OS benefit with dara x3 years in high-risk SMM. Monthly dara now can prevent Dara quad & ASCT later? Will be worth it in some patients! https://t.co/2PBwfRacuH https://t.co/KxhLx2C3HM
-
-
Mashup Score: 7Vincent Rajkumar: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma - OncoDaily - 1 day(s) ago
Vincent Rajkumar: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma / Albert Oriol, Andrew J Cowan, Anne K. Mylin, Annelore Cortoos,
Source: oncodaily.comCategories: General Medicine News, Partners & KOLsTweet-
RT @oncodaily: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma - @VincentRK https://t.co/hYfHWWab5r @thanosdimo…
-
-
Mashup Score: 4
Daratumumab significantly improved PFS, OS, but identity of high-risk population remains elusive
Source: www.medpagetoday.comCategories: General Medicine News, Partners & KOLsTweet-
RT @IMFjimMYELOMA: Treatment of Smoldering Myeloma Cuts Progression Rate in Half https://t.co/YGLOF1KzNi The biggest question is WHO should…
-
-
Mashup Score: 1Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma - 2 day(s) ago
Leukemia – Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma
Source: www.nature.comCategories: General Medicine News, Partners & KOLsTweet-
#ASH24 to the latter point (that T-cell fitness & phenotype at pheresis can help determine outcomes months later), similar work by German group with SOC ide-cel in @LeukemiaJnl earlier this year: https://t.co/pT04Yj9b8y
-
-
Mashup Score: 86
Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a…
Source: www.nejm.orgCategories: General Medicine News, Partners & KOLsTweet-
Out in @NEJM as @thanosdimop is speaking!! 🚨 Most important #ASH24 abstract in #MMsm: AQUILA study demonstrating OS benefit with dara x3 years in high-risk SMM. Monthly dara now can prevent Dara quad & ASCT later? Will be worth it in some patients! https://t.co/2PBwfRacuH https://t.co/KxhLx2C3HM
-
-
Mashup Score: 1
Previously, addition of isatuximab (Isa) to standard-of-care lenalidomide-bortezomib-dexamethasone (RVd) in transplant-eligible patients with newly diagnosed multiple myeloma in the GMMG-HD7 trial (ClinicalTrials.gov identifier: NCT03617731) resulted in a …
Source: ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
#ASH24 now published in @JCO_ASCO - congrats @EliasKarlMai and co-authors for tackling one of the most important unanswered #MMsm questions in our field! https://t.co/1maiXgatXJ https://t.co/cvYLczIYXu
-
Out in @NEJM as @thanosdimop is speaking!! 🚨 Most important #ASH24 abstract in #MMsm: AQUILA study demonstrating OS benefit with dara x3 years in high-risk SMM. Monthly dara now can prevent Dara quad & ASCT later? Will be worth it in some patients! https://t.co/2PBwfRacuH https://t.co/KxhLx2C3HM